Company Description
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis.
Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.
The company’s product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms.
It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand.
The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018.
Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
| Country | United States |
| Founded | 2005 |
| IPO Date | May 1, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 30 |
| CEO | Maria Palasis |
Contact Details
Address: 480 Arsenal Way Watertown, Massachusetts 02472 United States | |
| Phone | 617 393 4600 |
| Website | lyratherapeutics.com |
Stock Details
| Ticker Symbol | LYRA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001327273 |
| CUSIP Number | 55234L105 |
| ISIN Number | US55234L1052 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Maria Palasis Ph.D. | Chief Executive Officer, President and Director |
| Dr. Harlan W. Waksal M.D. | Executive Chairman |
| Jason Cavalier | Chief Financial Officer, Treasurer and Secretary |
| Dr. Carmichael S. Roberts Jr., Ph.D. | Co-Founder |
| Ronan P. O'Brien J.D. | Chief Legal Officer |
| Vineeta Belanger Ph.D. | Senior Vice President of Clinical Affairs |
| Dr. Robert Kern M.D. | Chief Clinical Advisor |
| Gloria Cosgrove | Senior Vice President of Quality |
| Allison Nance | Senior Vice President of Regulatory Affairs |
| Dr. Elazer R. Edelman FACC, M.D., Ph.D. | Vice President of Finance and Risk |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 9, 2025 | 144 | Filing |
| Apr 4, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 4, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 25, 2025 | PRE 14A | Other preliminary proxy statements |
| Mar 13, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 13, 2025 | 10-K | Annual Report |
| Mar 13, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Jan 10, 2025 | 8-K | Current Report |
| Dec 16, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |